申请人:E. R. Squibb & Sons, Inc.
公开号:US05827868A1
公开(公告)日:1998-10-27
Thromboxane receptor antagonist activity is exhibited by compounds of the formula ##STR1## wherein: V is --(CH.sub.2).sub.m --, --O--, or ##STR2## but if V is --O--or ##STR3## R.sup.3 and R.sup.4 must complete an aromatic ring; W is --(CH.sub.2).sub.2 --, --CH.dbd.CH-- or phenylene; X is a single bond, --CH.dbd.CH--, --(CH.sub.2).sub.n --, or --O--(CH.sub.2).sub.n --; or X is branched alkylene or --O--branched alkylene wherein W is linked to Y through a chain n carbon atoms long; Y is --CO.sub.2 H, --CO.sub.2 alkyl, --CO.sub.2 alkali metal, --CH.sub.2 OH, --CONHSO.sub.2 R.sup.5, --CONHR.sup.6, or --CH.sub.2 -5-tetrazolyl; Z is O or NH; R.sup.3 and R.sup.4 are each independently hydrogen or alkyl or R.sup.3 and R.sup.4 together complete a ring optionally substituted through a ring carbon with a halo, lower alkyl, phenyl, halo (lower alkyl), halophenyl, oxo or hydroxyl group; and the remaining symbols are as defined in the specification.
化合物的公式展示出血栓素受体拮抗剂活性,其公式为 ##STR1## 其中:V为--(CH.sub.2).sub.m --,--O--或##STR2## 但如果V为--O--或##STR3##,则R.sup.3和R.sup.4必须完成一个芳香环;W为--(CH.sub.2).sub.2 --,--CH.dbd.CH--或苯基;X为单键,--CH.dbd.CH--,--(CH.sub.2).sub.n --或--O--(CH.sub.2).sub.n --;或X为支链烷基或--O--支链烷基,其中W通过长度为n的链与Y连接;Y为--CO.sub.2 H,--CO.sub.2 烷基,--CO.sub.2 碱金属,--CH.sub.2 OH,--CONHSO.sub.2 R.sup.5,--CONHR.sup.6或--CH.sub.2-5-四氮唑基;Z为O或NH;R.sup.3和R.sup.4各自独立地为氢或烷基,或R.sup.3和R.sup.4一起完成一个环,该环可选择地通过环碳与卤素,较低的烷基,苯基,卤代(较低的烷基),卤代苯基,氧代或羟基基团进行取代;其余符号如规范中所定义。